EP 2305652 A3 20110803 - Trisubstituted quinazolinone derivatives as vanilloid antagonists

Title (en)

Trisubstituted quinazolinone derivatives as vanilloid antagonists

Title (de)

Trisubstituierte Chinazolinonderivate als Vanilloidantagonisten

Title (fr)

Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde

Publication

EP 2305652 A3 20110803 (EN)

Application

EP 10178992 A 20061206

Previously filed application

PCT/EP2006/011720 20061206 WO

Priority

EP 06829349 A 20061206
GB 0525068 A 20051208

Abstract (en)

[origin: WO2007065662A2] The present invention relates to quinazolinone compounds of the formula wherein R2, R3, R5, R6 R7 and R8 are as defined in the specification and in the claims, in free form or in salt form , processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.

IPC 8 full level

A61K 31/517 (2006.01); A61P 29/00 (2006.01); C07D 239/91 (2006.01); C07D 239/95 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01)

CPC (source: EP KR US)

A61K 31/517 (2013.01 - KR); A61P 1/04 (2017.12 - EP); A61P 1/08 (2017.12 - EP); A61P 1/10 (2017.12 - EP); A61P 1/12 (2017.12 - EP); A61P 1/18 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 19/06 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 39/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 239/91 (2013.01 - EP KR US); C07D 239/95 (2013.01 - EP KR US); C07D 401/04 (2013.01 - EP KR US); C07D 403/04 (2013.01 - EP KR US)

Citation (search report)

[I] WO 2005049613 A1 20050602 - MERCK SHARP & DOHME [GB], et al
[A] WO 2004005265 A1 20040115 - HOFFMANN LA ROCHE [CH]
[A] DE 239090 C
[X] US 2003220227 A1 20031127 - GUNGOR TIMUR [US], et al
[Y] US 4781750 A 19881101 - ASHMORE JOHN W [US]
[Y] US 5599814 A 19970204 - BARE THOMAS M [US], et al
[ADP] WO 2005120510 A1 20051222 - NOVARTIS AG [CH], et al
[X] SINHA S.K.P. ET AL., INDIAN J. CHEM. SECT. B, vol. 24, 1985, pages 1182-1184, XP009090428
[X] JOSHI H. ET AL., INDIAN J. CHEM. SECT. B, vol. 16, 1978, pages 1068-1070, XP009090429
[X] ERICSSON ET AL., ACTA PHARMACEUTICA SUECICA, vol. 10, no. 4, 1973, pages 257-262, XP009149414
[Y] PALANKI M S S ET AL: "The design and synthesis of novel orally active inhibitors of AP-1 and NF-kB mediated transcriptional activation. SAR of in vitro and in vivo studies", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 13, 1 January 2003 (2003-01-01), pages 4077 - 4080, XP002518652, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2003.08.047
[X] BOGERT M. T. ET AL., J. AM. CHEM. SOC, vol. 33, 1911, pages 949-962, XP002453809
[X] BOGERT M. T. ET AL., J. AM. CHEM. SOC, vol. 31, 1909, pages 1071-1078, XP002453810
[X] PEDERSEN, E. B.: "Phosphoramides; III. Phenyl N,N'-dimethylphosphorodiamidate as a new reagent for the synthesis of 3-methyl-4-oxo-3,4-dihydroquinazolines", SYNTHESIS , (3), 180-1, 1977, XP002453882

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2007065662 A2 20070614; WO 2007065662 A3 20080410; AU 2006322185 A1 20070614; BR PI0619540 A2 20111004; CA 2631438 A1 20070614; CN 101356160 A 20090128; EP 1963283 A2 20080903; EP 2305652 A2 20110406; EP 2305652 A3 20110803; GB 0525068 D0 20060118; JP 2009518338 A 20090507; KR 20080075028 A 20080813; RU 2008127257 A 20100120; US 2009082365 A1 20090326

DOCDB simple family (application)

EP 2006011720 W 20061206; AU 2006322185 A 20061206; BR PI0619540 A 20061206; CA 2631438 A 20061206; CN 200680050389 A 20061206; EP 06829349 A 20061206; EP 10178992 A 20061206; GB 0525068 A 20051208; JP 2008543725 A 20061206; KR 20087016434 A 20080707; RU 2008127257 A 20061206; US 9599506 A 20061206